ADS-5102

Certain chronic neurologic disorders produce hyper-and -hypo-kinetic movement during the day, for examples levodopa-induced dyskinesia, multiple sclerosis and others.  These progressive disorders are often accompanied by sleep disturbance at night.

Adamas is developing ADS-5102 as a chrono-synchronous amantadine therapy with potential applications across a number of chronic neurologic disorders. We are focusing initial development on the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD) and submitted a New Drug Application (NDA) for this indication to the U.S. Food and Drug Administration in October 2016.

We are also investigating ADS-5102 for the treatment of walking impairment in multiple sclerosis (MS) patients and considering developing it for other indications in PD, post stroke walking impairment, and side effects induced by anti-psychotic drugs, such as tardive dyskinesia, akathesia and weight gain.